When: Friday, September 25, 1:00 PM
Where: Tyler 108<\/p>\n\n\n\n
Abstract<\/strong> Bio<\/strong> Naitee published articles in Technometrics, Statistics in Medicine, Drug Information Journal (Therapeutic Innovation and Regulatory Science), Journal of Statistical Planning and Inference, Journal of Biopharmaceutical Statistics, Biometrical Journal, Statistics and Probability Letters, Statistics in Biosciences, Statistics in Biopharmaceutical Research, and Journal of Statistical Computation and Simulation. His book \u201cDose Finding in Drug Development\u201d was published in 2006 by Springer, and is considered as the leading reference in the field of dose response clinical trials. The book \u201cFundamental Concepts for New Clinical Trialists\u201d, co-authored with Scott Evans, was published by CRC in 2015. Another book \u201cPhase II Clinical Development of New Drugs\u201d, co-authored with Chen, Ho, and Cappelleri was published in 2017 (Springer). Naitee has been an active member of both the ASA and the International Chinese Statistical Association (ICSA).<\/p>\n","protected":false},"excerpt":{"rendered":" When: Friday, September 25, 1:00 PMWhere: Tyler 108 AbstractIn the process of medicine discovery and development, understanding the dose-response relationship is one of the most important and challenging tasks. It is critical to identify the right range of doses in early stages of medicine development so that Phase III trials can be properly designed to […]<\/p>\n","protected":false},"author":3300,"featured_media":19229,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[34,85],"tags":[],"class_list":["post-19226","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-seminars"],"acf":[],"_links":{"self":[{"href":"https:\/\/web.uri.edu\/cs\/wp-json\/wp\/v2\/posts\/19226","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/web.uri.edu\/cs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/web.uri.edu\/cs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/web.uri.edu\/cs\/wp-json\/wp\/v2\/users\/3300"}],"replies":[{"embeddable":true,"href":"https:\/\/web.uri.edu\/cs\/wp-json\/wp\/v2\/comments?post=19226"}],"version-history":[{"count":2,"href":"https:\/\/web.uri.edu\/cs\/wp-json\/wp\/v2\/posts\/19226\/revisions"}],"predecessor-version":[{"id":19228,"href":"https:\/\/web.uri.edu\/cs\/wp-json\/wp\/v2\/posts\/19226\/revisions\/19228"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/web.uri.edu\/cs\/wp-json\/wp\/v2\/media\/19229"}],"wp:attachment":[{"href":"https:\/\/web.uri.edu\/cs\/wp-json\/wp\/v2\/media?parent=19226"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/web.uri.edu\/cs\/wp-json\/wp\/v2\/categories?post=19226"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/web.uri.edu\/cs\/wp-json\/wp\/v2\/tags?post=19226"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
In the process of medicine discovery and development, understanding the dose-response relationship is one of the most important and challenging tasks. It is critical to identify the right range of doses in early stages of medicine development so that Phase III trials can be properly designed to confirm appropriate dose(s) for the patient. Usually in the beginning of Phase II development, there is limited information to help guide trial designs, therefore Phase II clinical trials often consists of objectives for establishing proof of concept (PoC), identifying a set of potentially safe and efficacious doses, and characterizing the dose-response relationship.<\/p>\n\n\n\n
Naitee Ting is a Fellow of American Statistical Association (ASA). Naitee is the recipient of the prestigious Mentoring Award of ASA in 2025. He is currently Vice President of Veramed. Naitee is also an Adjunct Professor of Department of Statistics at University of Connecticut, Adjunct Professor of Department of Biostatistics at Columbia University. He joined Veramed in 2025. Before Veramed, Naitee has been with Boehringer Ingelheim Pharmaceuticals, Inc. (BI) for 15 years, and he was working at Pfizer Inc. for 22 years (1987-2009). Naitee received his Ph.D. in 1987 from Colorado State University (major in Statistics). He has an M.S. degree from Mississippi State University (1979, Statistics) and a B.S. degree from College of Chinese Culture (1976, Forestry) at Taipei, Taiwan.<\/p>\n\n\n\n